Bio Innovation Conference | Pete Buzy
17670
page-template-default,page,page-id-17670,page-child,parent-pageid-16863,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-17.2,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-5.6,vc_responsive
 

Pete Buzy

Pete Buzy

President, Paragon Gene Therapy, Catalent Biologics

As an accomplished biotechnology executive and private equity investor, Pete Buzy is an industry veteran, who, most recently, has led one of Maryland’s fastest expanding biotech companies in the state.  Having joined Paragon Bioservices in 2014 as an investor and Chief Operating Officer, he later moved into the role of President & Chief Executive Officer. Bringing with him more than 25 years of successful executive leadership experience, Pete created a vision for Paragon that cultivated strategic and accelerated growth and ultimately led to the company becoming a premier player in the CDMO gene therapy space. His expertise in building strong and focused leadership teams and growing emerging technology companies was instrumental in the value creation of Paragon which resulted in its purchase by Catalent (NYSE: CTLT) in 2019 for $1.2B.  Paragon currently has over 700 employees and its sale was one of the largest PE backed transactions in the Mid-Atlantic region over the past decade. Catalent is the leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products.

Prior to joining Paragon, Pete spent more than 13 years as a senior executive at Martek Biosciences Corporation (NASDAQ: MATK), a leader in the innovation, development, production, and sale of high-value products from microbial sources. He played a key role in transforming Martek’s business from an R&D company to a fully integrated and profitable commercial organization with more than $470M in annual sales.  During his tenure as Executive Vice President & Chief Financial Officer, Pete successfully raised more than $300M in both private and public financing to support Martek’s substantial growth. He successfully oversaw several large corporate acquisitions, collaborations, and licensing arrangements, cultivating company growth while setting the stage for Martek’s sale to Royal DSM NV in 2011 for nearly $1.1B.

During his tenure at both Paragon and Martek, Pete has received numerous business awards including being named CEO of the year by both Paragon PE firms, Camden Partners and NewSpring Capital.  In addition, Paragon was named Life Science Company of the year by the Technology Council of Maryland in 2018.  Pete also received the Chief Financial Officer of the Year Award from the Technology Council of Maryland in 2011.

Prior to Martek, Pete spent 13 years at Ernst & Young where he advanced to Partner in the Northern Virginia High Technology and Life Science Practice, serving a variety of private and publicly traded biotechnology companies.   A prior member of Paragon’s Board, Pete received a BBA in Accounting from Salisbury University in Maryland and serves on the Board and Executive Committees of the Technology Council of Maryland.

STAY INFORMED. Join our mailing list to receive our email newsletter.